^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CLN-619

    i
    Associations
    News

    Trials

    Company:
    Cullinan Therap
    Drug class:
    γδ TCR modulator, MICA agonist, MICB agonist, NKG2D stimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (CLN-619-001) (NCT05117476)
    Phase 1
    Cullinan Therapeutics Inc.
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    10/29/2021
    Primary completion :
    03/01/2026
    Completion :
    06/01/2026
    EGFR • ALK
    |
    Keytruda (pembrolizumab) • CLN-619